Back to top
more

Celularity (CELU)

(Delayed Data from NSDQ)

$3.07 USD

3.07
239,088

-0.31 (-9.17%)

Updated Apr 25, 2024 04:00 PM ET

After-Market: $3.10 +0.03 (0.98%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (69 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

HOOKIPA Pharma Inc. (HOOK) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

HOOKIPA Pharma Inc. (HOOK) delivered earnings and revenue surprises of -12.50% and 15.31%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Shattuck Labs, Inc. (STTK) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Shattuck Labs, Inc. (STTK) delivered earnings and revenue surprises of 19.67% and 83.24%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Akoya Biosciences (AKYA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Akoya (AKYA) delivered earnings and revenue surprises of -6.52% and 5.11%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Arvinas, Inc. (ARVN) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -5.48% and 5.88%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Blueprint Medicines (BPMC) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 19.17% and 48.18%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Biogen (BIIB) Beats on Q1 Earnings, Ends Some Research Programs

by Zacks Equity Research

Biogen (BIIB) beats first-quarter estimates for earnings and sales. It maintains its 2023 guidance. Stock drops in pre-market trading.

Assertio (ASRT) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

On Assertio Therapeutics' (ASRT) Q1 earnings call, investors will likely focus on the sales performance of its rheumatology, pain and inflammation medicines.

Best Momentum Stocks to Buy for April 12th

by Zacks Equity Research

CELU, PPG and LSCC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on April 12, 2023.

New Strong Buy Stocks for April 12th

by Zacks Equity Research

CELU, MGI, LRMR, EQRX and SRZN have been added to the Zacks Rank #1 (Strong Buy) List on April 12, 2023.

Immuneering Corporation (IMRX) Surges 18.5%: Is This an Indication of Further Gains?

by Zacks Equity Research

Immuneering Corporation (IMRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Celularity, Inc. (CELU) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Celularity, Inc. (CELU) closed at $0.59, marking a -0.69% move from the previous day.

Celularity, Inc. (CELU) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

Celularity, Inc. (CELU) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Celularity (CELU) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Devoid of marketed drugs, investors will focus on updates on Celularity's (CELU) pipeline candidates when it reports its fourth-quarter earnings.

Investors Heavily Search Celularity, Inc. (CELU): Here is What You Need to Know

by Zacks Equity Research

Celularity, Inc. (CELU) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Celularity, Inc. (CELU) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Celularity, Inc. (CELU) closed at $0.74, marking a +1.36% move from the previous day.

Celularity, Inc. (CELU) Stock Moves -0.11%: What You Should Know

by Zacks Equity Research

Celularity, Inc. (CELU) closed at $0.64 in the latest trading session, marking a -0.11% move from the prior day.

Here is What to Know Beyond Why Celularity, Inc. (CELU) is a Trending Stock

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Celularity, Inc. (CELU). This makes it worthwhile to examine what the stock has in store.

Celularity, Inc. (CELU) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Celularity, Inc. (CELU) closed at $0.74 in the latest trading session, marking a +1.73% move from the prior day.

Celularity, Inc. (CELU) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Celularity, Inc. (CELU) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Celularity, Inc. (CELU) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

In the latest trading session, Celularity, Inc. (CELU) closed at $0.95, marking a -1.7% move from the previous day.

Celularity, Inc. (CELU) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

Zacks.com users have recently been watching Celularity, Inc. (CELU) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Mirati (MRTX) KRAS Candidate MRTX1133 to Enter Clinical Stage

by Zacks Equity Research

Mirati Therapeutics (MRTX) announces IND clearance for oral KRASG12D selective inhibitor, MRTX1133, by the FDA. It is set to initiate phase I/II study in early 2023.

Horizon (HZNP) Dazodalibep Meets Goal in Sjogren's Syndrome Study

by Zacks Equity Research

Horizon Therapeutics (HZNP) announces that a phase II Sjogren's syndrome study of its candidate, dazodalibep, meets the primary endpoint for the second population.

Angion (ANGN) Down on Merger Agreement With Private Biotech

by Zacks Equity Research

Angion (ANGN) inks a definitive merger agreement with privately-held Elicio Therapeutics. The combined company's lead pipeline candidate will be ELI-002, a therapeutic cancer vaccine targeting mKRAS-driven tumors.

Roche (RHHBY) Gets EU Approval for Xofluza in New Patient Base

by Zacks Equity Research

The European Commission approves Roche's (RHHBY) Xofluza for treating uncomplicated influenza and post-exposure prophylaxis of influenza in children aged one year and above.